Challenging Approach to the Development of Novel Estrogen Receptor Modulators Based on the Chemical Properties of Guaiazulene
- PMID: 35163039
- PMCID: PMC8835499
- DOI: 10.3390/ijms23031113
Challenging Approach to the Development of Novel Estrogen Receptor Modulators Based on the Chemical Properties of Guaiazulene
Abstract
Tamoxifen, a therapeutic agent for breast cancer, has been associated with genetic polymorphisms in the metabolism of N,N-dialkylaminoethyl substituent, which plays an important role in the expression of selective estrogen receptor modulator (SERM) activity. To solve this problem, we developed a novel estrogen receptor (ER) modulator, Az-01, on the basis of the aromaticity, dipole moment, and isopropyl group of guaiazulene. Az-01 showed four-fold lower binding affinity for ER than E2 but had similar ER-binding affinity to that of 4-hydroxytamoxifen (4-HOtam). Unlike tamoxifen, Az-01 acted as a partial agonist with very weak estrogenic activity at high concentrations when used alone, and it showed potent anti-estrogenic activity in the presence of E2. The cell proliferation and inhibition activities of Az-01 were specific to ER-expressing MCF-7 cells, and no effect of Az-01 on other cell proliferation signals was observed. These findings are important for the development of new types of SERMs without the N,N-dialkylaminoethyl substituent as a privileged functional group for SERMs.
Conflict of interest statement
The authors declare no conflict of interest.
Figures








Similar articles
-
Synthesis, structure-activity relationships and antagonistic effects in human MCF-7 breast cancer cells of flexible estrogen receptor modulators.Med Chem. 2005 Jul;1(4):335-53. doi: 10.2174/1573406054368666. Med Chem. 2005. PMID: 16789891
-
Mechanisms governing the accumulation of estrogen receptor alpha in MCF-7 breast cancer cells treated with hydroxytamoxifen and related antiestrogens.J Steroid Biochem Mol Biol. 2003 Nov;87(2-3):207-21. doi: 10.1016/j.jsbmb.2003.09.011. J Steroid Biochem Mol Biol. 2003. PMID: 14672741
-
A novel dual-target steroid sulfatase inhibitor and antiestrogen: SR 16157, a promising agent for the therapy of breast cancer.Breast Cancer Res Treat. 2007 Dec;106(2):191-203. doi: 10.1007/s10549-007-9494-y. Epub 2007 Feb 1. Breast Cancer Res Treat. 2007. PMID: 17268816
-
The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer.Best Pract Res Clin Endocrinol Metab. 2004 Mar;18(1):47-66. doi: 10.1016/j.beem.2003.08.002. Best Pract Res Clin Endocrinol Metab. 2004. PMID: 14687597 Review.
-
Potential of selective estrogen receptor modulators as treatments and preventives of breast cancer.Anticancer Agents Med Chem. 2009 Jun;9(5):481-99. doi: 10.2174/187152009788451833. Anticancer Agents Med Chem. 2009. PMID: 19519291 Free PMC article. Review.
References
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical